Vertex Pharmaceuticals management check
VRTX · Health Care · Biotechnology · CEO Reshma Kewalramani
Filings as of
Closest peers in Biotechnology
- 38GILDGilead Sciences83
- 50VRTXVertex Pharmaceuticals81
- 88REGNRegeneron Pharmaceuticals77
- 111AMGNAmgen76
- 208ABBVAbbVie68
- 300INCYIncyte61
- 405MRNAModerna53
- 439BIIBBiogen48
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
100100thDetail
$100 invested at the start of fiscal 2021 grew to $192, against $125 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9585thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.91 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.5% of net income
What does the CEO cost owners?
$21.1m pay · $4.0bn net income, FY2025
7375thDetail
$21.1m of reported pay in fiscal 2025, against $4.0bn of net income.
- WatchCEO stake ≈ 2.2 years of pay
Do they own the stock?
86,471 shares ≈ $46.0m
6 mo: ▲ $0 bought · ▼ $22.0m sold
5257thDetail
The CEO holds 86,471 shares, directly or through trusts (unvested awards not counted): about 2.2 years of pay. Light activity: no buys, $22.0m sold in six months. 13 of 13 sales ran on pre-arranged 10b5-1 plans.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −0.5% a year; flagged above +2%
Stock pay 5.7% of revenue
5643rdDetail
Diluted shares changed -0.5% a year over the last three fiscal years. Stock-based pay was 5.7% of revenue in the latest year.
- Good7 leadership filings in 3 years
Is leadership stable?
7 filings under 8-K 5.02 in 3 years
CEO: Reshma Kewalramani
9069thDetail
CEO in the pay table: Reshma Kewalramani. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed April 2, 2026.
Pay tied most to net product revenue
Other key measuresNet Product RevenuePipeline Progression(1)Adjusted Non-GAAP EBITDA(2)
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Reshma Kewalramani | $21.1m | $38.2m | $7.7m | $192 | $125 | $4.0bn |
| 2024 | Reshma Kewalramani | $21.5m | $43.6m | $8.1m | $170 | $93 | −$500.0m |
| 2023 | Reshma Kewalramani | $20.6m | $44.2m | $7.4m | $172 | $94 | $3.6bn |
| 2022 | Reshma Kewalramani | $15.9m | $29.5m | $9.0m | $122 | $90 | $3.3bn |
| 2021 | Reshma Kewalramani | $15.2m | $18.3m | $7.2m | $93 | $100 | $2.3bn |
Insiders and the CEO's stakeQuiet
- CEO & President
- Reshma Kewalramani
- Shares held
- 86,471
- At that filing's price
- ≈ $46.0m
- Latest Form 4
- Nov 6, 2026
Light activity: no buys, $22.0m sold in six months. 13 of 13 sales ran on pre-arranged 10b5-1 plans.
Open-market trades by officers and directors since May 21, 2026.
- SoldCharles F Jr WagnerEVP, CO & FO · 10b5-1 plan$8.4mNov 12, 2026
- SoldReshma KewalramaniCEO & President · 10b5-1 plan$6.3mNov 6, 2026
- SoldCarmen BozicEVP and CMO · 10b5-1 plan$4.3mJun 26, 2026
- SoldDuncan McKechnieEVP, Chief Commercial Officer · 10b5-1 plan$800kJul 2, 2026
Leadership and governance on file
All 8 filings
- Oct 20, 2026Leadership change8-K 5.02
- Sep 1, 2026Leadership change8-K 5.02
- May 13, 2026Leadership change8-K 5.02
- Apr 29, 2026Leadership change8-K 5.02
- Aug 4, 2025Leadership change8-K 5.02
- Feb 10, 2025Leadership change8-K 5.02
- Dec 5, 2023Leadership change8-K 5.02
- Oct 5, 2023Leadership change8-K 5.02
Latest shareholder vote results: May 13, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $5.0bn returned to owners in buybacks and dividends, 40% of net income, and $2.9bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $7.6bn | $8.9bn | $9.9bn | $11.0bn | $12.0bn |
| Net income | $2.3bn | $3.3bn | $3.6bn | −$535.6m | $4.0bn |
| Stock-based pay | $441.4m | $491.3m | $581.2m | $698.5m | $685.9m |
| Buybacks | $1.4bn | $0 | $427.6m | $1.2bn | $2.0bn |
| Dividends | — | — | — | — | — |
| Diluted shares | 260m | 259m | 261m | 258m | 258m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.